Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma

Trial Profile

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma

Suspended
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Etoposide (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary) ; Temozolomide (Primary) ; Cytarabine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 Results of plasma and cerebrospinal fluid pharmacokinetics of doxil (n=4) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 28 May 2016 Status changed from recruiting to suspended.
    • 08 Dec 2015 Interim results (n=11) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top